Advocacy intelligence hub — real-time data for patient organizations
The First Affiliated Hospital with Nanjing Medical University — EARLY_PHASE1
Peking University People's Hospital — PHASE3
Guangdong Ruishun Biotech Co., Ltd — PHASE1
Tongji Hospital — NA
Hebei Senlang Biotechnology Inc., Ltd. — PHASE2
The Children's Hospital of Zhejiang University School of Medicine — NA
Shandong University
First Affiliated Hospital of Zhejiang University — PHASE2
Institute of Hematology & Blood Diseases Hospital, China — NA
Miltenyi Biomedicine GmbH — NA
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Besponsa
(inotuzumab ozogamicin)Orphan drugWyeth Pharmaceuticals, LLC
CD22-directed Immunoconjugate [EPC]
12.1 Mechanism of Action Inotuzumab ozogamicin is a CD22-directed antibody drug conjugate (ADC). Inotuzumab recognizes human CD22. The small molecule,...
Browse all Precursor B-cell acute lymphoblastic leukemia news →
Prof. Dr. Michael Schmitt
University Hospital Heidelberg, Department V
Farhad Ravandi-Kashani, MD, M.D
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Prof. Dr. Andreas Kulozik
University Hospital Heidelberg, University Medical Center for Children and Adolescents
Paolo Caimi, MD, M.D
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
📍 CLEVELAND, OH
Thomas G. Martin, MD
University of California, San Francisco
Steven Devine, MD, MD
NMDP
📍 LA CROSSE, WI
View all Precursor B-cell acute lymphoblastic leukemia specialists →